Ring chromosome 15 syndrome is a rare condition in which severe growth retardation is a major finding. We report a 4 year old boy with the karyotype 46,XY, r(15)(pll.2q26.2) whom we have treated with recombinant human growth hormone (GH) for two years. During the first year oftreatment, the insulin-like growth factor I increased from subnormal 4-2 nmol/I to normal 13 8 nmol/l and the insulin-like growth factor binding protein 3 levels increased from 2*6 to 3 8 mg/l, whereas high binding protein 1 concentrations normalised from 52 0 to 16-7 ttgIl. During the two years of treatment his relative height improved from -6*2 SD to -4.4 SD and the predicted adult height from 159-6cm to 163-5 cm. Owing to the good growth response, we have decided to continue GH treatment. (J Med Genet 1995;32:486-487) 
Ring chromosome 15 is a rare condition resulting from breakage and closure of chromosomal material leading to a ring formation and loss of genetic material. ' Table 2 Growth parameters, IGF-I, IGFBP-1, and IGFBP-3 concentrations dunrng GH treatment started at the age of 2 years. Age related reference values for IGF-1, IGFBP-1, and IGFBP-3 from our own laboratory (range, n= 10) are given in parentheses under each parameter As far as we know, there have been no previous reports published on the results of GH therapy in the ring chromosome 15 syndrome. Our results suggest that GH therapy improves growth and predicted final height considerably in this syndrome, and we have therefore decided to continue treatment. This seems to be justified, since growth retardation is severe in most cases and may complicate everyday activities of these patients as adults.' However, the decision on possible GH treatment should be made taking into account the complete spectrum of symptoms, for example, the degree of mental retardation, characteristic of this syndrome.
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